3-year-old's quick-spreading cancer cured thanks to new treatment

Key Points:

• A 3-year-old boy with chemo-resistant hepatoblastoma, a childhood liver cancer that had spread to his lungs and possibly bones, was declared cancer-free after two doses of an experimental CAR T-cell therapy called GPC3-CAR.
• The therapy genetically engineers a patient’s T cells to target cancer, and after eight weeks of treatment, the boy showed complete regression of the disease with no signs after one year.
• This breakthrough marks a significant advancement as CAR T-cell therapy has previously been limited in treating solid tumors due to tumor defenses, with prior FDA approval only for certain blood cancers.
• The study, published in The New England Journal of Medicine by researchers at Texas Children’s, Baylor College of Medicine, and Seattle Children’s, highlights the potential safety and effectiveness of GPC3-CAR therapy for hepatoblastoma and other GPC3+ solid tumors.
• Further research and clinical trials, including the ongoing CARE study at Baylor College of Medicine, are underway to evaluate the broader applicability and safety of this innovative treatment for pediatric solid tumors.